CClinicalTrials.gg
CompletedNCT00540046Updated Feb 9, 2015Results posted

Immediate vs. Delayed Insertion of Copper T 380A IUD After Termination of Pregnancy Over 12-weeks Gestation

An interventional study of Copper T 380A IUD in Contraception Behavior, sponsored by NYU Langone Health. Completed at 2 sites in United States. Open to female participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-09.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
16 Years and older
Sex
Female
01

Study summary

The purpose of this study is to compare delayed vs. immediate insertion of the Copper T 380 IUD after termination of pregnancy after 12 weeks.

Read the detailed description

Patients presenting to ParkMed Women's Clinic and the Reproductive Choice clinic at Bellevue Hospital for second trimester termination will be offered participation in this study. They will be randomized to either delayed or immediate Copper T 380A IUD insertion. The subjects will be seen at a 6 month follow-up visit and Copper T 380A IUD placement will be verified by physical exam. At this 6 month follow-up visit, subjects will fill out a satisfaction questionnaire.

02

Conditions studied

  • Contraception Behavior

Keywords

  • IUD
  • Second trimester termination
  • Contraception
03

In context

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • women 16 years of age and older
  • intrauterine pregnancy > 14 weeks gestation
  • desires termination of pregnancy
  • desires IUD for contraception
  • ability to give informed consent
  • no contraindication for D+E

Exclusion criteria

Exclusion Criteria:

  • unable to give informed consent
  • less than 16 years of age
  • congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity
  • acute pelvic inflammatory disease (PID)
  • known or suspected uterine or cervical neoplasia or unresolved abnormal PAP smear
  • untreated acute cervicitis or vaginitis, until infection treated/controlled
  • confirmed Chlamydia trachomatis or Neisseria gonorrhea infection in the previous 90 days
  • acute liver disease or liver tumor (benign or malignant)
  • woman or partner currently with multiple sexual partners
  • history of Wilson's disease
  • hypersensitivity to any component of Copper T IUD
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
215 participants (actual)

Study arms

  • Active comparator
    A/Immediate

    The patients in the immediate arm will have the Copper T 380A IUD inserted within 15 minutes after delivery of the placenta immediately following procedure

    Device: Copper T 380A IUD

  • Active comparator
    B/Delayed

    The delayed group will have the Copper T 380A IUD inserted at the post-operative visit within 2-4 weeks following the procedure.

    Device: Copper T 380A IUD

Interventions

  • DeviceCopper T 380A IUD

    Copper T 380A IUD will be placed at the 2-4 week post-operative visit.

06

What researchers measure

Primary outcomes

  1. Use of IUD

    Number of participants using Copper T380A IUD 6 months after surgery

    Time frame: 6 months

Secondary outcomes

  1. Expulsion

    IUD was not removed by provider but fell out on its own.

    Time frame: 6 months

07

Results

Posted Jan 13, 2015
Limitations and caveats
IUD presence not always confirmed by a provider at 6-month visit but self-reported. Study not powered to detect a difference in expulsion rates due to prohibitively high sample size. Very high-risk population.

Participant flow

Participant flow — Overall Study
MilestoneA/ImmediateB/Delayed
Started104111
Completed7188
Not completed3323
Withdrew: Lost to follow-up3323

Outcome measures

PrimaryUse of IUD

Number of participants using Copper T380A IUD 6 months after surgery

Time frame:
6 months
Reported as:
Number · participants
Use of IUD
participantsA/ImmediateB/Delayed
Use of IUD5825
SecondaryExpulsion

IUD was not removed by provider but fell out on its own.

Time frame:
6 months
Reported as:
Number · percentage of expulsions
Expulsion
percentage of expulsionsA/ImmediateB/Delayed
Expulsion3.10

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A/Immediate—0/104 (0%)2/104 (1.9%)
B/Delayed—0/111 (0%)0/111 (0%)
Most frequent other events
Most frequent other events
EventA/ImmediateB/Delayed
ExpulsionReproductive system and breast disorders2/1040/111

Baseline characteristics

215 subjects were enrolled and randomized to the A/Immediate or B/Delayed group.

Age, Continuous
Age, Continuous(years)A/ImmediateB/DelayedTotal
Mean24 (16 to 41)23.4 (16 to 43)23.7 (16 to 43)
Sex/Gender, Customized
Sex/Gender, Customized(participants)A/ImmediateB/DelayedTotal
Female104111215
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)A/ImmediateB/DelayedTotal
Black4852100
Hispanic or Latino433982
White4610
Asian or South Asian145
Mixed459
Other235
Missing224
Gestational age
Gestational age(weeks)A/ImmediateB/DelayedTotal
Mean19.2 (12 to 24)18.8 (12 to 24)19.0 (12 to 24)
08

Study locations

2 sites
  • Bellevue Hospital
    New York, New York 10016, United States
  • Parkmed Women's Clinic
    New York, New York 10017, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00540046
Lead sponsor
NYU Langone Health
Collaborators
Icahn School of Medicine at Mount Sinai
Responsible party
Miriam Cremer (Clinical Assistant Professor, NYU Langone Health) — Principal investigator
First posted
Oct 5, 2007
Start date
Apr 2007
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Jan 13, 2015
Last update
Feb 9, 2015

Study contacts

Miriam L. Cremer, MD, MPH
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion